NCT06605625

Vaccine Responses in Cancer

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 250 (estimated)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.

Detailed description

Vaccinations are indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. In particular, immune responses following vaccination have not been studied in the setting of cancer and in the context of various anti-tumor treatments. In this study, the investigators will look at the immune response of subjects receiving vaccination.

Conditions

• Viral Vaccines

Interventions

Type	Name	Description
BIOLOGICAL	Influenza vaccination	one annual dose of inactivated influenza vaccine
BIOLOGICAL	SARS-CoV-2 vaccine	dose of SARS CoV2 vaccine
BIOLOGICAL	Zoster Vaccine Recombinant	first and/or second vaccination for shingles (Herpes zoster)

Timeline

• Start date: 2022-11-04
• Primary completion: 2027-10-01
• Completion: 2028-10-01
• First posted: 2024-09-20
• Last updated: 2025-10-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study